<DOC>
	<DOCNO>NCT00961090</DOCNO>
	<brief_summary>A one time oral dose ALA take surgery . The medication make tumor visible ultraviolet light allow surgeon see tumor complete removal .</brief_summary>
	<brief_title>Safety Study Aminolevulinic Acid ( ALA ) Improve Visibility Brain Tumors During Surgery</brief_title>
	<detailed_description>Patients primary neoplastic brain tumor ( Grades II-IV ) participate trial . Each patient evaluate found tumor history recent imaging study ( MRI ) deem surgical candidate base current neurosurgical standard care .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Suspected primary brain tumor 18 year age Normal marrow organ function Life expectancy consideration Receiving investigational agent History allergic reaction ALA Personal family history porphyria Liver disease past year Uncontrolled intercurrent illness Pregnant lactate woman Inability undergo MRI contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>glioma</keyword>
	<keyword>surgical resection</keyword>
	<keyword>ALA</keyword>
	<keyword>ultraviolet light</keyword>
</DOC>